3 results
Primary objective is to investigate the feasibility of Hexvix® blue light URS. Secondary objectives are to determine the diagnostic value of Hexvix® blue light URS as compared to digital and fiberoptic white light URS, and to assess safety and…
The primary aim of the trial is to demonstrate the non-inferiority of CSL222 (formerly AMT-061) (2 × 1013 gc/kg) during the 52 weeks following establishment of stable factor IX expression (months 6 to 18) post-treatment (CSL222 (formerly AMT-061))…
The primary objective is reducing treatment-related morbidity and mortality without adversely impacting DFS in Ph+ ALL patients, classified as Standard Risk (SR) based on low minimal residual disease (MRD) at week 10-12 of therapy.Because there is…